OncoNano Medicine Achieves Milestone with First Patient Dosed in Phase 1 Trial for ONM-501 in Advanced Solid Tumors and Lymphomas

OncoNano Medicine, Inc. has announced the commencement of its Phase 1 clinical trial, with the first patient dosed at the University of Pittsburgh Medical Center (UPMC). The trial aims to evaluate ONM-501, a dual-activating polyvalent STING agonist designed for immuno-oncology applications and formulated with OMNI™, the company’s core immune activating polymer technology.

Kartik Krishnan, MD., PhD, President & Head of R&D for OncoNano Medicine, expressed enthusiasm, stating, “This marks an exciting milestone in the development of ONM-501, with preclinical data supporting enduring STING activation and the potential for an improved clinical profile compared to earlier experimental cyclic dinucleotide STING agonists. The initiation of our first human trial for ONM-501 brings us one step closer to providing cancer patients with our differentiated approach to targeted therapeutics.'"